Doubling Dolutegravir Dosage Reduces HIV Viral Reservoir in Suppressed Patients
Key Insights
Doubling dolutegravir dosage in HIV (search) patients on suppressive antiretroviral therapy (search) significantly reduced four key HIV reservoir markers in peripheral blood, including total HIV DNA and intact HIV DNA.
The intensified treatment also decreased immune activation and exhaustion markers, suggesting that standard ART (search) regimens may not completely prevent ongoing viral replication.
Results provide evidence for residual HIV (search) replication despite undetectable plasma viral loads and may inform future HIV cure strategies and clinical management approaches.
A randomized controlled study has demonstrated that doubling the dosage of dolutegravir (DTG) in HIV (search) patients with suppressed viral loads significantly reduces viral reservoir markers and immune activation, providing new evidence that standard antiretroviral therapy (search) may not completely prevent ongoing HIV replication.
The study, published in eLife, enrolled 20 people with HIV (search) who had been suppressed on DTG-containing ART (search) for at least 2 years with undetectable plasma viral loads. Participants were randomized to either continue their standard regimen or receive double the DTG dosage (100 mg daily instead of 50 mg) for 84 days.
Significant Reservoir Reduction Observed
Researchers measured multiple HIV (search) reservoir markers and found that doubling DTG dosage led to significant decreases in four key parameters in peripheral blood mononuclear cells (PBMCs):
- Total HIV DNA levels decreased significantly in the intensified group
- Intact HIV DNA, representing replication-competent virus, showed substantial reduction
- Unspliced (US) HIV RNA levels declined markedly
- The US RNA/total DNA ratio, indicating reservoir transcriptional activity, decreased significantly
These reductions were not observed in the control group, which maintained standard DTG dosing. The findings strongly suggest that pre-intensification ART (search) regimens were not completely suppressive, allowing for ongoing low-level viral replication.
Immune System Benefits
Beyond viral reservoir reduction, DTG intensification produced measurable improvements in immune markers. The treatment modestly but significantly reduced:
- Percentages of CD4+ T cells expressing TIGIT, a T-cell exhaustion marker previously shown to be enriched for HIV persistence
- Percentages of CD8+ T cells co-expressing CD38 and HLA-DR, established T-cell activation markers
The researchers noted that changes in HIV (search) reservoir activity correlated positively with changes in immune activation, exhaustion, and inflammation markers, suggesting a direct link between reservoir size and chronic immune dysfunction.
Evidence for Ongoing Replication
The study addresses a long-standing debate about whether HIV (search) continues to replicate at low levels despite suppressive ART (search). Previous intensification studies using different approaches have yielded conflicting results, with some showing benefits and others finding no effect.
This research is notable for being the first ART (search) intensification study to increase the dosage of an existing drug rather than adding a new medication. The approach revealed that even highly potent DTG-based regimens, considered among the most effective HIV (search) treatments available, may not achieve complete viral suppression.
Plasma and tissue DTG concentrations increased significantly in the intensified group, confirming drug exposure. However, the study found no effect on HIV (search) DNA in rectal tissue, possibly due to lower drug penetration in tissue compartments or the predominance of abortive infection events in lymphoid tissues.
Clinical Implications
The findings have potential implications for HIV (search) treatment and cure research. If ongoing viral replication contributes to reservoir persistence, as this study suggests, then optimizing ART (search) regimens could be crucial for HIV cure strategies.
The researchers noted that approaches aimed at eliminating viral reservoirs, such as "shock-and-kill" strategies, may be less effective if the virus continues to replicate despite treatment. In worst-case scenarios, residual replication could replenish HIV (search) reservoirs even as cure interventions attempt to deplete them.
The study used a DTG dosage of 100 mg daily, which is already recommended in clinical practice for patients with integrase inhibitor resistance. Based on these results, the researchers suggest that increased DTG dosing might be warranted as part of standard regimens even in patients without resistance, though they caution that intensification caused a transient decrease in the CD4/CD8 ratio.
Study Limitations and Future Directions
The researchers acknowledged several limitations, including the small sample size of 20 participants and lack of blinding or placebo control. The study population was predominantly male, and no post-intervention follow-up was conducted.
Despite these limitations, the convergence of effects across multiple reservoir markers in the same direction suggests a meaningful biological signal. The researchers emphasized that these findings should be considered exploratory and hypothesis-generating, warranting confirmation in larger, placebo-controlled, and blinded trials.
The study's strength lies in its comprehensive measurement of 30 biomarkers at five time points, providing detailed longitudinal analysis of both viral and immunological parameters. This approach allowed researchers to observe significant impacts on both virus and host that might have been missed with less extensive monitoring.
These results contribute to growing evidence that achieving complete HIV (search) suppression remains challenging even with the most potent available therapies, and suggest that treatment intensification strategies may play a role in future HIV cure efforts.